Townsend v Epsom and St Helier University Hospitals NHS Trust: No “Clinical Decision” Carve‑Out—Life‑Sustaining Treatment for Incapacitous Adults Must Be Determined Under MCA Best Interests, with Court of Protection Resolution Where Disputed

1. Introduction

This Court of Appeal decision arose from an urgent end-of-life dispute concerning Robert Barnor (“RB”), a 68-year-old man who, after multiple strokes, suffered extensive and irreversible brain damage and never regained consciousness. RB’s treating clinicians at Epsom and St Helier University Hospitals NHS Trust (“the Trust”) concluded that ongoing haemodialysis was futile/clinically inappropriate and should stop. RB’s family, led by his daughter Mrs Lesley Townsend (“the Appellant”), disputed both RB’s prognosis and the decision to discontinue dialysis, asserting signs of responsiveness and raising concerns about consultation, disclosure, and process.

The immediate procedural issue was whether the Appellant should be given permission under s.50(2) Mental Capacity Act 2005 (“MCA”) to bring proceedings in the Court of Protection about RB’s life-sustaining treatment. The Vice-President of the Court of Protection (Theis J) refused permission, reasoning that the Trust had made a “clinical decision” not to offer dialysis and therefore there was “no option” for the Court of Protection to consider.

The Court of Appeal granted permission to appeal on grounds challenging that approach, allowed the appeal, and granted s.50 permission so the disputed life-sustaining treatment issue could be determined urgently by a different Tier 3 Court of Protection judge. The Court refused interim relief compelling dialysis. RB died shortly thereafter, before any best interests determination could occur, but the Court of Appeal nevertheless laid down important guidance on the proper legal framework.

2. Summary of the Judgment

  • No carve-out for “clinical decisions”: The Court held that any decision about the care and treatment of an incapacitous adult—including decisions framed as “clinical”—must be taken under the MCA’s best interests framework.
  • Disputed life-sustaining treatment must go to Court of Protection: Where there is disagreement (family vs clinicians and/or experts) about withdrawal/withholding of life-sustaining treatment that cannot be resolved, the dispute must be referred to the Court of Protection; the Trust cannot pre-empt court scrutiny by re-labelling the matter as a non-justiciable “clinical decision.”
  • Trust’s reliance on first-instance authority criticised: The Trust’s approach, bolstered by reliance on Re AA (Withdrawal of Life-Sustaining Treatment: No Best Interests Decision) [2024] EWCOP 39 (T3), was held inconsistent with binding Supreme Court authority and established guidance.
  • s.50 permission should rarely be refused in life-sustaining treatment disputes: Refusing an initial permission application in a life-sustaining treatment dispute will be exceptional; the correct response is ordinarily to permit proceedings and then manage them robustly through case management powers.
  • Limits remain: The Court reaffirmed that the Court of Protection cannot compel clinicians to deliver treatment they consider clinically inappropriate; however, the best interests decision and the resolution of the dispute is for the Court, not unilateral clinical assertion.
  • Interim relief refused: Interim declarations effectively compelling dialysis were refused, because (among other reasons) they would be short-lived, risked invasive harm, and would amount in substance to ordering clinicians to deliver treatment they considered inappropriate.

3. Analysis

3.1 Precedents Cited

R (Burke) v General Medical Council (Official Solicitor and other intervening) [2005] EWCA Civ 1003, [2006] QB 273

The Trust relied on Burke to support a staged distinction: (1) clinician determines what is on offer (clinical appropriateness), (2) patient decides (or, if incapacitous, best interests decision is made), (3) treatment is provided. Burke is important for the proposition that a doctor is not legally obliged to provide treatment considered not clinically indicated, and should offer a second opinion.

The Court of Appeal in Townsend did not reject Burke’s core proposition (no compulsion to provide non-indicated treatment). Instead, it held that in the MCA context—especially for life-sustaining treatment disputes—Burke cannot be used to remove contested withdrawal/withholding decisions from MCA best interests scrutiny. In short: non-compellability of treatment does not entail non-justiciability of the decision-making process when P lacks capacity and life is at stake.

Airedale NHS Trust v Bland [1993] AC 789

Bland was invoked for its foundational procedural insight: absent court involvement, clinicians risk becoming “judge in [their] own cause” when proposing cessation of life-support in a best interests framework. While modern practice has evolved (particularly after An NHS Trust & Ors v Y & Anor [2018] UKSC 46), Townsend reaffirms Bland’s constitutional concern in disputed cases: when disagreement persists, the legitimacy of the outcome depends on accessible, authoritative court resolution.

Aintree University Hospital NHS Foundation Trust v James [2013] UKSC 67, [2014] AC 591

Aintree was central. The Court of Appeal drew from Baroness Hale’s analysis that the legal focus is on whether it is lawful to give treatment (i.e., whether giving it is in best interests), rather than treating withholding/withdrawal as a separate category outside best interests. This supported two key moves in Townsend:

  • Best interests is unavoidable: if treatment is not in best interests, the court cannot consent to it on P’s behalf, and it will follow that it is lawful to withhold/withdraw; the analysis is inherently a best interests evaluation.
  • MCA s.5 relevance: the clinician’s protection from liability depends on a reasonable belief that acts done are in best interests—underscoring that best interests is embedded in the legal architecture of treatment decisions for incapacitous adults.

N v ACCG and others [2017] UKSC 22, [2017] AC 549

The Trust relied on N v ACCG for the “available options” principle: the Court of Protection can only choose between options that are actually available; it cannot compel provision/funding beyond that. The Court of Appeal accepted the principle, but emphasised Lady Hale’s equally important guidance that case management is for the court, not for providers to pre-empt by declaring an option unavailable. In other words, “available options” is not a licence for a public body to shut down adjudication by unilateral fiat; it is a constraint on remedies once the court has properly seized and managed the dispute.

An NHS Trust & Ors v Y & Anor [2018] UKSC 46

Y provided the modern framework: court applications are not required in every case of withdrawal of clinically assisted nutrition and hydration (CANH) where there is agreement and proper process, but where there is doubt, disagreement, a difference of medical opinion, or a finely balanced decision, an application “can and should be made”. Townsend treated Y as decisive against the Trust’s stance, criticising the Trust’s legal exposition for omitting Lady Black’s clear articulation and instead relying heavily on conflicting first-instance reasoning.

R v Spectrum Community Health Community Interest Co ex parte JJ [2023] EWCA Civ 885, [2024] PTSR 1

This authority was cited as part of the Trust’s submission that clinical decisions are reviewable (if at all) by judicial review rather than Court of Protection proceedings. Townsend distinguished the point in context: even if some “purely clinical” decisions may fall for public law review, the decision to withhold/withdraw life-sustaining treatment from an incapacitous person where there is dispute is not properly expelled from the MCA best interests framework. The Court’s reasoning makes clear that forum selection cannot be driven by unilateral characterisation where the MCA best interests duty is engaged.

Lambert v France (2016) 62 EHRR 2

The Appellant invoked Lambert to reinforce the Article 2 dimension: domestic law must provide a compatible framework, must consider the patient’s wishes and those close to him, and must preserve the possibility of approaching the courts in case of doubt. Although the Court said Article 2 submissions “add little of substance” beyond the core analysis, Lambert functioned as an important interpretive backdrop: access to an effective court process in disputed life-sustaining treatment decisions is integral to Convention-compliant safeguards.

An NHS Trust v MB [2006] EWHC 507 (Fam)

The Trust cited a brief proposition that a judge cannot require doctors to carry out a positive medical intervention against their judgment. The Court of Appeal noted that this was a child case and that, properly read, it sat within an “exhaustive analysis” of best interests. It could not bear the weight the Trust placed upon it as a route to avoid Court of Protection scrutiny.

GUP v EUP & Anor [2024] EWCOP 3

Hayden J’s reasoning in GUP supported the proposition that where there is conflict, a decision not to provide nutrition can be “every bit as serious” as withdrawal, and such cases “must be resolved by the court.” Townsend aligned with that stance, effectively treating it as consistent with higher authority and with the Vice-President’s 2020 Guidance.

Re AA (Withdrawal of Life-Sustaining Treatment: No Best Interests Decision) [2024] EWCOP 39 (T3)

This first-instance decision was the pivot of the Trust’s strategy: if there is “only one available option,” the court allegedly has “no choice” and therefore no best interests decision to make; declarations would be “purposeless.” The Court of Appeal expressly rejected that approach as inconsistent with “principles and practice” found in binding case law, the MCA Code, and established guidance. The Court’s criticism signals that Re AA should not be used as authority to avoid judicial determination in contested life-sustaining treatment cases.

Abbasi v Newcastle upon Tyne Hospitals NHS Foundation Trust [2025] UKSC 15

Abbasi featured on transparency issues. The Court accepted that protection of treating clinicians’ identities can be justified during proceedings and for a short “cooling off” period afterwards, but deferred the wider relaxation request pending proper party/litigation friend arrangements. While not central to the life-sustaining treatment principle, it reflects current appellate emphasis on balancing open justice with clinician protection in a polarised public environment.

3.2 Legal Reasoning

The Court’s legal reasoning turns on an integrated reading of the MCA and the appellate medical treatment jurisprudence:

(a) Statutory anchor: MCA ss.1, 4, 5, 15, 16 and s.50

  • s.1(4) MCA is treated as a controlling principle: any act/decision “under this Act” for an incapacitous person must be in best interests.
  • s.4 MCA supplies the structured checklist for best interests, including the life-sustaining treatment caution in s.4(5) (no motivation to bring about death), and the duty to consider wishes, feelings, beliefs, values, and consult those interested in welfare.
  • s.5 MCA is crucial: it provides legal protection for acts done in connection with care/treatment where the actor reasonably believes P lacks capacity and the act is in P’s best interests. The Court used this to reinforce that “best interests” is not an optional overlay but a legal condition of lawful intervention for incapacitous patients.
  • ss.15–16 MCA empower the Court of Protection to make declarations about lawfulness (including omissions and courses of conduct) and to make decisions on behalf of P.
  • s.50 MCA (permission for non-entitled applicants) was applied in a strongly pro-access way: in a life-sustaining treatment dispute, the “benefit” of resolving disagreement through court determination will almost always satisfy s.50(3), making refusal of initial permission exceptional.

(b) The Court’s core holding: disagreement triggers Court of Protection adjudication

The Court distilled “clearly and consistently established” principles (its own numbered list) and applied them to hold that the Trust’s “clinical decision/not on offer” framing could not deprive RB of a best interests determination where the family disputed the course. The Court treated the dispute itself as the trigger: if disagreement persists after discussion/mediation, the proper route is an application to the Court of Protection, generally to be brought (and funded) by the responsible NHS body, not by the family.

(c) Preserving limits: no judicial compulsion to provide non-indicated treatment

The Court maintained the boundary that the Court of Protection cannot compel doctors to deliver treatment they consider clinically inappropriate. But it separated:

  • Remedial limits (court cannot order a doctor to provide a treatment against professional judgment), from
  • Adjudicative necessity (court must be able to determine best interests and lawfulness where life-sustaining treatment is disputed).

In practical terms, the Court’s approach ensures that clinicians are not forced to provide treatment, but also ensures that contested end-of-life decisions are not insulated from legal standards, evidential scrutiny, and procedural fairness by the mere label “clinical decision.”

(d) Case management, not permission refusal, is the proper control mechanism

The Court acknowledged that some cases may be capable of swift resolution and that proceedings can be abbreviated (drawing on N v ACCG and others [2017] UKSC 22, [2017] AC 549). But it insisted that it is for the court—not the provider—to decide what “useful purpose” further process will serve. This is why refusing s.50 permission at the threshold was characterised as a misstep: it displaced the judicial role in managing and resolving a serious, disputed life-sustaining treatment decision.

3.3 Impact

  • Closes a procedural avoidance route: NHS bodies and advisers are put on clear notice that they cannot avoid Court of Protection scrutiny in disputed life-sustaining treatment cases by asserting “no best interests decision” because a treatment is “not on offer.”
  • Recalibrates reliance on Re AA: The Court of Appeal’s express disapproval substantially weakens Re AA (Withdrawal of Life-Sustaining Treatment: No Best Interests Decision) [2024] EWCOP 39 (T3) as a basis for resisting Court of Protection involvement where disagreement exists.
  • Lowers the threshold barrier for families via s.50: While the Court reaffirmed that commissioning bodies should bring and fund applications, it also signalled that where a family must apply (because the Trust refuses), permission should generally be granted so the dispute can be adjudicated rather than blocked.
  • Strengthens process expectations: The decision implicitly reinforces good practice on disclosure, second opinions, consultation, and mediation. Even though the Court did not finally determine best interests, its reasoning indicates that procedural deficits will not support a provider’s attempt to keep disputes out of court.
  • Transparency ramifications: The decision confirms a cautious approach to relaxing anonymity mid-proceedings, especially where a litigation friend has not yet been appointed, while recognising (via Abbasi v Newcastle upon Tyne Hospitals NHS Foundation Trust [2025] UKSC 15) continued protection for treating clinicians.

4. Complex Concepts Simplified

“Best interests” (MCA)
A legal test requiring decision-makers to consider the person’s welfare in the widest sense—medical, emotional, social, and psychological—alongside the person’s own values, wishes, and beliefs (so far as ascertainable), and the views of those close to them (MCA s.4; Aintree University Hospital NHS Foundation Trust v James [2013] UKSC 67, [2014] AC 591).
“Life-sustaining treatment”
Treatment which, in the clinician’s view, is necessary to sustain life (MCA s.4(10)). Dialysis in this case was treated as life-sustaining.
“Clinical decision” vs “best interests decision”
Clinicians often decide what treatments are medically indicated; however, where an adult lacks capacity, the lawfulness of giving (and thus of withholding) serious treatment is anchored in best interests. Townsend rejects the notion that labelling a decision “clinical” removes it from MCA best interests analysis in disputed life-sustaining treatment contexts.
s.50 permission
Family members (without LPA/deputyship) typically need the Court’s permission to apply to the Court of Protection. The Court of Appeal indicated that, in an initial disputed life-sustaining treatment case, permission should be granted save in exceptional circumstances; disputes should be resolved via judicial determination and case management, not blocked at the gate.
Why the Court refused interim relief
Interim declarations sought would, in effect, have required invasive steps to restart dialysis and would have functioned like an order compelling clinicians to provide treatment they considered inappropriate. The Court also considered the short time until the remitted hearing and the risks of harm from line insertion.

5. Conclusion

Townsend v Epsom and St Helier University Hospitals NHS Trust establishes (and forcefully reasserts) that there is no “clinical decision” carve-out from the MCA when life-sustaining treatment for an incapacitous adult is in dispute. While courts cannot compel clinicians to provide treatment they consider clinically inappropriate, the lawfulness and best interests of withholding or withdrawing life-sustaining treatment—where contested—must be resolved through the MCA framework and, if disagreement persists, by the Court of Protection. The decision also signals that s.50 permission should not be used to prevent adjudication of an initial life-sustaining treatment dispute; instead, courts should grant permission and then deploy robust case management to secure an efficient, proportionate, and rights-compliant resolution.